BiondVax to start pivotal universal flu vaccine trial next year
BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) expects to be Phase 3 ready in 2018 to begin pivotal testing in Europe of a universal flu vaccine with the potential to provide multi-season and...
View ArticleClik here to view.
BiondVax begins NIH-sponsored universal flu vaccine trial
BiondVax Pharmaceuticals (NASDAQ:BVXV) enrolled the first participant in a U.S. Phase 2 clinical trial of its universal flu vaccine candidate, M-001. The trial is sponsored by the U.S. National...
View ArticleClik here to view.
NIH Phase 2 trial of BiondVax universal flu vaccine hits both primary endpoints
A Phase 2 trial supported by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) concluded that BiondVax Pharmaceuticals’ (NASDAQ:BVXV) M-001 universal influenza vaccine candidate...
View ArticleClik here to view.
BiondVax universal flu vaccine fails Phase 3 trial
A Phase 3 clinical trial of BiondVax Pharmaceuticals’ (NASDAQ:BVXV) M-001 universal flu vaccine did not demonstrate a statistically significant difference between the vaccinated and placebo groups in...
View Article
